The Dual Specificity Role of Transcription Factor FOXO in Type 2-diabetes and Cancer

Author(s): Kaneez Fatima, Shilu Mathew, Muhammed Faheem, Tahir Mehmood, Hadi Mohamad Yassine, Asmaa A. Al Thani, Hany Abdel-Hafiz, Khalid Al Ghamdy, Ishtiaq Qadri*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 24 , 2018

Become EABM
Become Reviewer
Call for Editor


The FOXO (Forkhead box O) transcription factors are implicated in several signaling pathways and play a vital role in various cellular and physiological processes include for instance, ROS (reactive oxygen species) response, cell proliferation, regulation of programmed cell death, longevity, metabolism and cancer and regulation of cell cycle. In humans, the four FOXO family members are responsible for resemblance in their structure, regulation and functions. FOXO1 gene is highly expressed in adipose tissues and it affects the regulation of glycogenolysis and gluconeogenesis through insulin signaling. The gene of FOXO3 is highly expressed in the kidney, heart, spleen and brain and is characterized as diverse forkhead DNA-binding domain of transcription factors. The FOXO3 is a tumor suppressor gene and found to interact with p53, the trigger for apoptosis through BCl2 family genes and a regulator of Notch signaling pathway for the self-renewal of stem cells. Therefore, FOXOs remains to be a fascinating and potential target to acquire novel therapeutic approaches to cure cancer. This review will provide a comprehensive overview about the biology of FOXO proteins, which can be utilized for developing current therapeutic approaches to treat cancer.

Keywords: Forkhead box O, therapeutic, cancer, polymorphism, transcription factors, cell proliferation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 November, 2018
Page: [2839 - 2848]
Pages: 10
DOI: 10.2174/1381612824666180911114210
Price: $65

Article Metrics

PDF: 49